Spitfire List Web site and blog of anti-fascist researcher and radio personality Dave Emory.
The tag 'Pfizer' is associated with 2 posts.

FTR #1166 Bio-Psy-Op Apocalypse Now, Part 22: A Pound of Cure, Part 1

Sup­ple­ment­ing FTR #1138, this pro­gram con­tin­ues dis­cus­sion about drug treat­ments for, and vac­cines to pre­vent, Covid-19.

In pre­vi­ous posts and pro­grams, we have not­ed that Mod­er­na’s vac­cine work has been financed by DARPA. We have also not­ed that the over­all head of Oper­a­tion Warp Speed is Mon­cef Slaoui, for­mer­ly in charge of prod­uct devel­op­ment for Mod­er­na!

Of great sig­nif­i­cance is the cen­tral role of the mil­i­tary in the devel­op­ment of treat­ment for Covid-19:

1.–The pro­gram notes that: ” . . . . Remde­sivir pre­dates this pan­dem­ic. It was first con­sid­ered as a poten­tial treat­ment for Ebo­la, and was devel­oped through a long­stand­ing part­ner­ship between the U.S. Army and the Cen­ters for Dis­ease Con­trol and Pre­ven­tion. . . .”
2.–Jonathan King has sound­ed the alarm about “vac­cine research” mask­ing offen­sive bio­log­i­cal war­fare research: “. . . . King, who has chaired the micro­bial phys­i­ol­o­gy study sec­tion for the NIH, believes that with­out inten­sive inde­pen­dent scruti­ny, the Pen­ta­gon is free to obscure its true goals. ‘The Defense Depart­ment appears to be pur­su­ing many nar­row, applied goals that are by nature offen­sive, such as the genet­ic ‘improve­ment’ of BW agents,’ King says. ‘But to achieve polit­i­cal accept­abil­i­ty, they mask these inten­tions under forms of research, such as vac­cine devel­op­ment, which sound defen­sive. . . .”
3.–Moderna’s vac­cine devel­op­ment was over­seen by an unnamed Pen­ta­gon offi­cial: ” . . . . Moderna’s team was head­ed by a Defense Depart­ment offi­cial whom com­pa­ny exec­u­tives described only as ‘the major,’ say­ing they don’t know if his name is sup­posed to be a secret. . . . .”
4.–The per­va­sive role of the mil­i­tary in Oper­a­tion Warp Speed (the Trump admin­is­tra­tion’s vac­cine devel­op­ment pro­gram) has gen­er­at­ed alarm in civil­ian par­tic­i­pants: “. . . . Scores of Defense Depart­ment employ­ees are laced through the gov­ern­ment offices involved in the effort, mak­ing up a large por­tion of the fed­er­al per­son­nel devot­ed to the effort.  Those num­bers have led some cur­rent and for­mer offi­cials at the Cen­ters for Dis­ease Con­trol and Pre­ven­tion to pri­vate­ly grum­ble that the military’s role in Oper­a­tion Warp Speed was too large for a task that is, at its core, a pub­lic health cam­paign. . . .”
5.–General Gus­tave Perna–one of the prin­ci­pals in Oper­a­tion Warp Speed–has cho­sen a retired Lieu­tenant Gen­er­al to over­see much of the pro­gram: ” . . . . ‘Frankly, it has been breath­tak­ing to watch,’ said Paul Ostrows­ki, the direc­tor of sup­ply, pro­duc­tion and dis­tri­b­u­tion for Oper­a­tion Warp Speed. He is a retired Army lieu­tenant gen­er­al who was select­ed to man­age logis­tics for the pro­gram by Gen. Gus­tave F. Per­na, the chief oper­at­ing offi­cer for Oper­a­tion Warp Speed. . . .”
6.–The mil­i­tary will be able to trace the des­ti­na­tion and admin­is­tra­tion of each dose: ” . . . . Mil­i­tary offi­cials also came up with the clever idea — if it works — to coor­di­nate the deliv­ery of vac­cines to drug­stores, med­ical cen­ters and oth­er immu­niza­tion sites by send­ing kits full of nee­dles, syringes and alco­hol wipes. Vac­cine mak­ers will be alert­ed when the kits arrive at an immu­niza­tion site so they know to ship dos­es. Once the first dose is giv­en, the man­u­fac­tur­er will be noti­fied so it can send the sec­ond dose with a patient’s name attached sev­er­al weeks lat­er. The mil­i­tary will also mon­i­tor vac­cine dis­tri­b­u­tion through an oper­a­tions cen­ter. ‘They will know where every vac­cine dose is,’ Mr. [Paul] Man­go said on a call with reporters. . . .”

This pro­gram begins with infor­ma­tion about the ongo­ing pro­fes­sion­al mas­sag­ing of Gilead Sci­ences’ anti-viral remde­sivir.

The most pos­i­tive stud­ies have proved remdesivir/Veklury only mod­est­ly suc­cess­ful against SARS Cov‑2 (the virus that caus­es Covid-19). Remde­sivir (now mar­ket­ed under the brand name Vek­lury) has been pro­pelled to the fore­front of treat­ment reg­i­mens for the pan­dem­ic, a devel­op­ment which appears to dimin­ish the chances for a com­pet­ing, more effec­tive drug to gain pro­fes­sion­al approval for treat­ing Covid-19.

” . . . . Oth­er stud­ies have shown no ben­e­fit, includ­ing the World Health Organization’s Sol­i­dar­i­ty tri­al, released as a preprint on Oct. 15. Based on these results, the Euro­pean Soci­ety of Inten­sive Care Med­i­cine is now rec­om­mend­ing that the drug not be rou­tine­ly used in hos­pi­tal­ized Covid-19 patients. Infec­tious dis­ease experts have stat­ed that after exam­in­ing all avail­able evi­dence, we can rea­son­ably con­clude only that remde­sivir may work. . . .”

Deeply dis­turb­ing, as well, is the news that the “pos­i­tive news” about vac­cine suc­cess and devel­op­ment has been gen­er­at­ed by press releas­es from the com­pa­nies that man­u­fac­ture them: ” . . . . But the com­pa­nies announced the find­ings in news releas­es, not in peer-reviewed sci­en­tif­ic jour­nals, and did not dis­close the detailed data that would allow out­side experts to eval­u­ate their claims. There­fore, the results can­not be con­sid­ered con­clu­sive. The fig­ures on effec­tive­ness may change as the stud­ies con­tin­ue. . . .”

Pro­gram High­lights Include: The rapid spread of the dis­ease is ben­e­fit­ting the speed-up of vac­cine research; review of the atten­u­at­ed, manip­u­lat­ed NIAID study on remde­sivir that gen­er­at­ed pos­i­tive news, a run-up in the stock price of Gilead Sci­ences and a boost for the mar­ket as a whole; review of the role of “Sci­en­tists to Stop Covid-19” in mas­sag­ing the vet­ting process for remde­sivir; review of the CDC’s clos­ing of the USAMRIID in August of 2019 and the test­ing of remdeisivir at that facil­i­ty in March of 2019; review of the insid­i­ous, inces­tu­ous rela­tion­ship between the author­i­ties “reg­u­lat­ing” treat­ment of Lyme Dis­ease and those who ben­e­fit from the admin­is­tra­tion of that treat­ment; review of Lyme Dis­ease as a bio­log­i­cal war­fare weapon.

Cancer Warfare

Nation­al Can­cer Insti­tute and the Fort Det­rick Link Richard Hatch Covert Action Infor­ma­tion Bul­letin Num­ber 39 (Win­ter 1991–92) Those who would increase the poten­cy of bio­log­i­cal weapons must search for improved meth­ods o f mass pro­duc­tion of organ­isms, fac­tors which will enhance the vir­u­lence, ways to pro­long the stor­age life of liv­ing agents, ways to […]